Brief: Medadvisor Says Completed Strategic Review Of Its Operations

Adheris Health

22/06/2023 02:05

June 22 (Reuters) - Medadvisor Ltd  MDR.AX :
    * COMPLETED A STRATEGIC REVIEW OF ITS OPERATIONS
    * FY23 REVENUE EXPECTED TO BE IN RANGE OF A$95 MILLION TO
A$97
MILLION
    * PLANS TO REDUCE ITS AUSTRALIAN HEADCOUNT BY APPROXIMATELY
20% BY
END OF JUNE 2023
    * FY 23 EBITDA LOSS EXPECTED TO BE IN RANGE A$3.5 MILLION TO
A$3.0
MILLION
    * REDUCTION IN HEADCOUNT UNDERPINS ANNUAL COST SAVINGS OF
CIRCA
A$2 MILLION FOR FY24
    * HAS POSITIONED ITSELF FOR PROFITABILITY IN FY24
    * COMPANY'S CURRENT US PIPELINE IS MATERIALLY ABOVE PREVIOUS
CORRESPONDING PERIOD

Source text for Eikon:  ID:nASX8PSw6w 
Further company coverage:  MDR.AX 

 ((Reuters.Briefs@thomsonreuters.com;))